Edgewise Therapeutics, Inc.

Equities

EWTX

US28036F1057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
17.05 ^USD	+5.44%		+13.06%	+55.85%

Apr. 23	Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU	MT
Apr. 22	RBC Raises Price Target on Edgewise Therapeutics to $32 From $28, Keeps Outperform, Speculative Risk	MT

Edgewise Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

February 22, 2024 at 08:00 am EST

Edgewise Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 30.14 million. Basic loss per share from continuing operations was USD 0.47.

Latest news about Edgewise Therapeutics, Inc.

Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU	Apr. 23	MT
RBC Raises Price Target on Edgewise Therapeutics to $32 From $28, Keeps Outperform, Speculative Risk	Apr. 22	MT
Sector Update: Health Care Stocks Mixed Premarket Tuesday	Apr. 16	MT
Edgewise Therapeutics Reports 'Positive' Two-Year Results From Becker Muscular Dystrophy Trial	Apr. 15	MT
Edgewise Therapeutics, Inc. Announces Positive Two-Year Topline Results from the Arch Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy	Apr. 15	CI
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session	Mar. 28	CI
Piper Sandler Starts Edgewise Therapeutics With Overweight Rating, $48 Price Target	Mar. 07	MT
Wedbush Raises Edgewise Therapeutics' PT to $26 From $23, Continues to See 2024 as Critical Year; Keeps Outperform Rating	Feb. 23	MT
Edgewise Therapeutics Full Year 2023 Net Loss Widens	Feb. 22	MT
Edgewise Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Edgewise Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Edgewise Therapeutics Drug Candidate to Treat Duchenne Gets FDA's Fast Track Designation	Feb. 13	MT
Edgewise Shares Rise Premarket on FDA Fast-Track Designation	Feb. 13	DJ
Edgewise Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy	Feb. 13	CI
Edgewise Therapeutics Insider Sold Shares Worth $596,805, According to a Recent SEC Filing	Feb. 09	MT
Edgewise Therapeutics Insider Sold Shares Worth $1,419,759, According to a Recent SEC Filing	Jan. 25	MT
Edgewise Therapeutics Insider Bought Shares Worth $4,999,995, According to a Recent SEC Filing	Jan. 25	MT
Top Midday Gainers	Jan. 19	MT
Edgewise Therapeutics Surging After Pricing $240 Million Stock Sale Above Last Close	Jan. 19	MT
Edgewise Therapeutics Insider Sold Shares Worth $1,610,097, According to a Recent SEC Filing	Dec. 28	MT
Edgewise Says US FDA Grants Orphan Drug, Rare Pediatric Disease Designations for Investigational Muscular Dystrophy Therapy	Nov. 30	MT
Edgewise Gets FDA Orphan, Rare-Pediatric-Disease Designations for Muscular-Dystrophy Program	Nov. 30	DJ
Edgewise Therapeutics, Inc. Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA	Nov. 30	CI
Wedbush Lowers Edgewise Therapeutics' PT to $23 From $27, Sees 2024 as 'Critical' Year; Keeps Outperform Rating	Nov. 10	MT
Edgewise Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI

Chart Edgewise Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing novel therapeutics for muscular dystrophies and serious cardiac conditions. It has built its muscle-focused drug discovery platform. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. Its lead product candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy. Its product candidate, EDG-7500, for the treatment of hypertrophic cardiomyopathy addition to exploring the potential of its mechanism in the treatment of disorders of diastolic dysfunction.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.17 USD

Average target price

31.17 USD

Spread / Average Target

+92.74%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EDGEWISE THERAPEUTICS, INC.	+55.85%	1.51B
IQVIA HOLDINGS INC.	+1.77%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+12.24%	41.34B
CELLTRION, INC.	-8.83%	26.59B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.12B
MEDPACE HOLDINGS, INC.	+30.56%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.35%	11B

Other Biotechnology & Medical Research